However, inhibiting TLK2 leads to the downregulation of ERα, BCL2, and SKP2, causing cell cycle arrest in the G1/S phase and ultimately triggering apoptosis, which can help improve the prognosis of patients with breast cancer (Kim et al., 2016b). Here, SKP2 is linked to breast cancer.